HEALTHglobal
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial
Single source
Updated 2 hours ago
First seen March 16, 2026 23:10:16Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks.